Texas Diagnostic Laboratories LLC

Texas Diagnostic Laboratories LLC was paid $920K by Medicaid between Dec 2020 and Dec 2024, across 80 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 54% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Texas

Rank by total paid#73 of 436

Median peer was paid$17K

This provider vs. median53×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	30	$100.00
2021	10,027	$53K
2022	26,406	$736K
2023	14,640	$42K
2024incomplete	18,853	$88K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	54%	12,368	8,100	$496K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	18%	12,212	7,984	$163K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	14%	11,635	7,656	$132K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	5.8%	4,259	2,982	$53K
87481		1.8%	2,666	2,040	$17K
87631		1.1%	865	636	$10K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	785	572	$6K
87500		<1%	2,633	2,003	$6K
87641		<1%	2,518	1,967	$5K
87640		<1%	2,600	1,985	$4K
87653		<1%	2,276	1,704	$4K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	523	342	$4K

68 more codes

87486		<1%	866	$3K
87581		<1%	866	$3K
87541		<1%	866	$3K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	1,508	$2K
87498		<1%	785	$2K
87483		<1%	674	$2K
86738		<1%	1,458	$1K
81226		<1%	157	$811.64
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	617	$786.89
86780		<1%	1,171	$679.47
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	205	$640.00
81225		<1%	158	$524.45
87529		<1%	299	$455.20
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	601	$415.99
87563		<1%	601	$325.79
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	599	$299.83
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	536	$268.25
87505		<1%	16	$256.58
87511		<1%	295	$198.13
81231		<1%	159	$174.81
81328		<1%	159	$174.81
81241		<1%	158	$146.74
81240		<1%	159	$131.38
81003		<1%	34	$16.20
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	106	$14.80
82565		<1%	103	$8.18
82947		<1%	81	$6.28
80053	Comprehensive metabolic panel	<1%	19	$4.75
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	0%	68	$0.00
87493		0%	89	$0.00
82435		0%	36	$0.00
84443	Thyroid stimulating hormone (TSH)	0%	56	$0.00
82040		0%	64	$0.00
83036	Hemoglobin; glycosylated (A1C)	0%	75	$0.00
87507		0%	73	$0.00
81283		0%	15	$0.00
84478		0%	41	$0.00
81350		0%	15	$0.00
81400		0%	15	$0.00
84075		0%	32	$0.00
81383		0%	15	$0.00
81377		0%	15	$0.00
84132		0%	67	$0.00
81374		0%	15	$0.00
81227		0%	15	$0.00
81306		0%	15	$0.00
81256		0%	15	$0.00
87329		0%	73	$0.00
82248		0%	35	$0.00
84295		0%	67	$0.00
82374		0%	48	$0.00
82247		0%	31	$0.00
84155		0%	13	$0.00
81479	Unlisted molecular pathology procedure	0%	75	$0.00
81381		0%	15	$0.00
84520		0%	65	$0.00
81232		0%	15	$0.00
82310		0%	13	$0.00
81406		0%	15	$0.00
81335		0%	15	$0.00
84450		0%	32	$0.00
81249		0%	15	$0.00
81355		0%	15	$0.00
81401		0%	15	$0.00
84460		0%	13	$0.00
82465		0%	28	$0.00
83540		0%	12	$0.00
81220	CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants	0%	14	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialDALAL, SHEHZAD (COO)